FDA halts Unum's phase I trial again due to safety concerns July 5, 2019 By Lee Landenberger No Comments The FDA placed a clinical hold Wednesday on a phase I trial by Unum Therapeutics Inc. after a patient experienced serious adverse events that included grade 3 neurotoxicity and cytomegalovirus infection, and grade 4 respiratory distress.Read More